Oxford Biomedica Signs Three Year Master Services & Development Agreement with Astrazeneca to Manufacture COVID-19 Vaccines
Shots:
- The companies have entered into a 3yr. agreement to manufacture AstraZeneca’s COVID-19 vaccines in the future. The recent agreement is an extension of the 2020 master supply & development agreement
- AstraZeneca will have access to Oxford Biomedica’s Oxbox manufacturing facility to produce its vaccine on an as-needed basis beyond 2022 which is expected to complete in Q4’22. Oxford anticipates total revenues of ~$36.2M from AstraZeneca in the present financial year under the terms of the original agreement
- Under the Sept 2020 agreement, Oxford received $18.1M up front as a capacity reservation fee & an additional revenue over $36.58M along with materials costs for the manufacture of multiple large-scale batches of AZD1222
Ref: Oxford Biomedica | Image: Astrazeneca
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
